FDA approves Arcutis' skin foam for seborrheic dermatitis

The US Food and Drug Administration (FDA) has approved a topical foam developed by Arcutis Biotherapeutics and branded as Zoryve for the skin condition seborrheic dermatitis in people aged nine years and up.

Related Keywords

Pennsylvania , United States , China , , Particle Sciences , Sterling Pharma Solutions , Partners Group , Particle Science , Snapdragon Chemistry , Clinical Development , Drug Delivery , Linical Evolution , Fda , Food And Drug Administration , Small Molecule Drugs ,